ArticleBMC infectious diseases2022
Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- Article
- Diagnostic accuracy of sputum smear microscopy compared with culture in patients with tuberculosis confirmed by XpertThe Journal of international medical research · 2025Article
- Potential auxiliary diagnostic role of pentraxin 3 in plasma and bronchoalveolar lavage fluid for pulmonary tuberculosis.Journal of cardiothoracic surgery · 2025Article
- Diagnostic performance of Ziehl-Neelsen staining and Auramine-Rhodamine staining techniques in the detection of pulmonary and extrapulmonary tuberculosis.Revista peruana de medicina experimental y salud publica · 2025Article
- CARPDM: cost-effective antibiotic resistome profiling of metagenomic samples using targeted enrichment.Applied and environmental microbiology · 2025Article
- Xpert MTB/RIF Ultra Ct Value: A Quick Indicator of Sputum Bacillary Load and Smear Status Prediction in Individuals with Pulmonary Tuberculosis.The East African health research journal · 2025Article
- Trends and treatment outcomes of drug resistant tuberculosis in Limpopo Province, South Africa (2011-2019): A Retrospective Study.PloS one · 2025Article
- CD137 in tuberculosis: a scoping review of an emerging immune checkpoint at the crossroads of diagnosis, prognosis, and therapy.Frontiers in immunology · 2025Article
- Comparison of microscopic and xpert MTB diagnoses of presumptive mycobacteria tuberculosis infection: retrospective analysis of routine diagnosis at Cape Coast Teaching Hospital.BMC infectious diseases · 2024Article
- Article
- Article
- Frequency of fungal pathogens in autopsy studies of people who died with HIV in Africa: a scoping review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2024Article
- Evaluating the Sensitivity of Different Molecular Techniques for DetectingPolish journal of microbiology · 2023Article
- Rapid Detection of Mycobacterium Tuberculosis Using a Novel Point-of-Care BZ TB/NTM NALF Assay: Integrating LAMP and LFIA Technologies.Diagnostics (Basel, Switzerland) · 2023Article
- Detection ofPathogens (Basel, Switzerland) · 2023Article
- The Burden of Bacteriologically Negative TB Diagnosis: A Four-Year Review of Tuberculosis Cases at a Tertiary Facility.Tuberculosis research and treatment · 2023Article
- Article
- Evaluation of the use of GeneXpert MTB/RIF in a zone with high burden of tuberculosis in Thailand.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) is a leading cause of morbidity and mortality worldwide. Control of TB is lingering by the lack of diagnostic tests that are simple, rapid, yet accurate. Thus, smear-negative pulmonary TB often misses the diagnosis. The study evaluated the performance of GeneXpert MTB/RIF assay for the detection of Mycobacterium tuberculosis (MTB).
methodsThe study was carried out from June to December 2016 in Nepal Tuberculosis Center, Bhaktapur, Nepal. A total of 173 sputum samples were collected and processed by microscopy [Auramine-O staining and Ziehl-Neelsen (ZN) staining], followed by GeneXpert MTB/RIF assay and culture in Lowenstein-Jensen (LJ) medium.
resultsOf 173 sputum samples, 162 (93.6%) were smear-negative. Of 162 smear-negative sputum samples, 35 (21.6%) were confirmed to have MTB by culture, and 31 (19.1%) by GeneXpert MTB/RIF assay. Of 31 GeneXpert-positive samples, 25 (80.6%) were susceptible, 4 (12.9%) were resistant, and 2 (6.45%) were intermediate to rifampicin. The sensitivity, specificity, positive predictive value, and negative predictive value of GeneXpert MTB/RIF assay for smear-negative sputum samples were 74.3%, 96.6%, 86.7%, and 92%, respectively. The GeneXpert MTB/RIF has a substantial diagnostic agreement of 90.91% with culture (Cohen's Kappa coefficient = 0.73).
conclusionThe diagnostic performance of GeneXpert MTB/RIF assay was almost on par with culture, and thus can be relied upon for MTB detection in smear-negative sputum samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.